000164534 001__ 164534
000164534 005__ 20230915090551.0
000164534 0247_ $$2pmc$$apmc:PMC9288738
000164534 0247_ $$2doi$$a10.1002/ehf2.13986
000164534 0247_ $$2pmid$$apmid:35611842
000164534 0247_ $$2altmetric$$aaltmetric:128862341
000164534 037__ $$aDZNE-2022-01083
000164534 041__ $$aEnglish
000164534 082__ $$a610
000164534 1001_ $$00000-0001-8092-5967$$aTraub, Jan$$b0
000164534 245__ $$aSerum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure.
000164534 260__ $$aChichester$$bWiley$$c2022
000164534 3367_ $$2DRIVER$$aarticle
000164534 3367_ $$2DataCite$$aOutput Types/Journal article
000164534 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1658322649_13896
000164534 3367_ $$2BibTeX$$aARTICLE
000164534 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164534 3367_ $$00$$2EndNote$$aJournal Article
000164534 520__ $$aCognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF.Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = -4.7; P < 0.001), alanine aminotransferase (T = -2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = -3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025).Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF.
000164534 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164534 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164534 650_7 $$2Other$$aBrain atrophy
000164534 650_7 $$2Other$$aChronic heart failure
000164534 650_7 $$2Other$$aCognitive decline
000164534 650_7 $$2Other$$aGFAP
000164534 650_7 $$2Other$$aGlial fibrillary acidic protein
000164534 650_7 $$2Other$$aMemory dysfunction
000164534 650_2 $$2MeSH$$aAged
000164534 650_2 $$2MeSH$$aAtrophy
000164534 650_2 $$2MeSH$$aBiomarkers
000164534 650_2 $$2MeSH$$aFemale
000164534 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: metabolism
000164534 650_2 $$2MeSH$$aHeart Failure: complications
000164534 650_2 $$2MeSH$$aHeart Failure: diagnosis
000164534 650_2 $$2MeSH$$aHumans
000164534 650_2 $$2MeSH$$aMale
000164534 650_2 $$2MeSH$$aMemory Disorders: diagnosis
000164534 650_2 $$2MeSH$$aMemory Disorders: etiology
000164534 650_2 $$2MeSH$$aMiddle Aged
000164534 650_2 $$2MeSH$$aProspective Studies
000164534 7001_ $$aOtto, Markus$$b1
000164534 7001_ $$aSell, Roxane$$b2
000164534 7001_ $$aHomola, György A$$b3
000164534 7001_ $$aSteinacker, Petra$$b4
000164534 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b5$$udzne
000164534 7001_ $$aMorbach, Caroline$$b6
000164534 7001_ $$aFrantz, Stefan$$b7
000164534 7001_ $$aPham, Mirko$$b8
000164534 7001_ $$aStörk, Stefan$$b9
000164534 7001_ $$aStoll, Guido$$b10
000164534 7001_ $$aFrey, Anna$$b11
000164534 773__ $$0PERI:(DE-600)2814355-3$$a10.1002/ehf2.13986$$gp. ehf2.13986$$n4$$p2626-2634$$tESC heart failure$$v9$$x2055-5822$$y2022
000164534 8564_ $$uhttps://pub.dzne.de/record/164534/files/Serum%20glial%20fibrillary%20acidic%20protein%20indicates%20memory%20impairment%20in%20patients%20with%20chronic%20heart%20failure.pdf$$yOpenAccess
000164534 8564_ $$uhttps://pub.dzne.de/record/164534/files/Serum%20glial%20fibrillary%20acidic%20protein%20indicates%20memory%20impairment%20in%20patients%20with%20chronic%20heart%20failure.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164534 909CO $$ooai:pub.dzne.de:164534$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000164534 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000164534 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164534 9141_ $$y2022
000164534 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000164534 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000164534 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000164534 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164534 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000164534 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2021-02-03
000164534 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESC HEART FAIL : 2021$$d2022-11-09
000164534 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000164534 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000164534 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:20Z
000164534 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:20Z
000164534 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-04-16T15:13:20Z
000164534 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000164534 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000164534 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-09
000164534 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-09
000164534 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000164534 980__ $$ajournal
000164534 980__ $$aVDB
000164534 980__ $$aI:(DE-2719)5000073
000164534 980__ $$aUNRESTRICTED
000164534 9801_ $$aFullTexts